Evidence map›Paper›PMID 33133056›Full record

ArticleFrontiers in immunology2020

Antimicrobial Peptide Induced-Stress Renders

Alexandro Rodríguez-Rojas, Arpita Nath, Baydaa El Shazely, Greta Santi, Joshua Jay Kim, Christoph Weise, Benno Kuropka, Jens Rolff

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Halogenated Pyrrolopyrimidines with Low MIC onAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Alexandro Rodríguez-RojasInstitut für Biologie, Evolutionary Biology, Freie Universität Berlin, Berlin, Germany.
Arpita NathInstitut für Biologie, Evolutionary Biology, Freie Universität Berlin, Berlin, Germany.
Baydaa El ShazelyInstitut für Biologie, Evolutionary Biology, Freie Universität Berlin, Berlin, Germany.
Greta SantiInstitut für Biologie, Evolutionary Biology, Freie Universität Berlin, Berlin, Germany.
Joshua Jay KimInstitut für Biologie, Evolutionary Biology, Freie Universität Berlin, Berlin, Germany.
Christoph WeiseInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Benno KuropkaInstitute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
Jens RolffInstitut für Biologie, Evolutionary Biology, Freie Universität Berlin, Berlin, Germany.
Freie Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cationic antimicrobial peptides (AMPs) are active immune effectors of multicellular organisms and are also considered as new antimicrobial drug candidates. One of the problems encountered when developing AMPs as drugs is the difficulty of reaching sufficient killing concentrations under physiological conditions. Here, using pexiganan, a cationic peptide derived from a host defense peptide of the African clawed frog and the first AMP developed into an antibacterial drug, we studied whether sub-lethal effects of AMPs can be harnessed to devise treatment combinations. We studied the pexiganan stress response of

Indexed as

Anti-Bacterial AgentsAntimetabolitesAntimicrobial Cationic PeptidesBacterial ProteinsDeoxycytidineDrug Therapy, CombinationFluorouracilGemcitabineGene Expression Regulation, BacterialMicrobial Sensitivity TestsMicrobial ViabilityNucleosidesProteomeStaphylococcus aureusStress, PhysiologicalThioguanineAnti-Bacterial AgentsAntimetabolitesAntimicrobial Cationic PeptidesazauracilBacterial ProteinsDeoxycytidineFluorouracilGemcitabineNucleosidespexigananProteomeThioguanineUracilantibiotic resistanceantibioticsantimetabolitesantimicrobial peptidesnuceloside analogspexiganan

Identifiers

PMID33133056
PMCPMC7550632
OpenAlexW3090027375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.